Frontline Libtayo Could Help Patients with Advanced Cutaneous Squamous Cell Carcinoma Avoid Surgery
Автор: curetoday
Загружено: 2020-08-21
Просмотров: 1991
Описание:
Promising results of a single-institution, retrospective study examining the use of of Libtayo (cemiplimab) in the first line of treatment for patients with locally advanced cutaneous squamous cell carcinoma (CSCC) has led some experts to believe that the drug could help prevent potentially disfiguring surgeries in this patient population.
In a recent interview with OncLive, CURE’s sister publication, Dr. Jennifer L. Atlas, a medical oncologist in hematology and medical oncology at Levine Cancer Institute, of Atrium Health, explained how the 72% overall response rate found in patients treated with Libtayo was particularly positive for those whose tumors were located in the head and neck area.
View more at http://curetoday.com/
CURE: Combining science and humanity to make cancer understandable.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
![Плоскоклеточный рак [дерматология]](https://imager.clipsaver.ru/DYHImpEuAVM/max.jpg)
